ALNY
NASDAQ · Biotechnology
Alnylam Pharmaceuticals Inc
$251.65
+7.33 (+3.00%)
ALNY News4 articles
Alnylam Shares Tumble 28% After Slashing Amvuttra Revenue Forecast
Shares of Alnylam Pharmaceuticals fell 28% after the firm lowered its Amvuttra revenue outlook, erasing $10.9 billion in equity value.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Ionis Plunges 23% After Wainua Misses Key Goal in Heart Disease Trial
Ionis stock tumbled 23% after Wainua missed its primary endpoint in a major heart disease trial, erasing $3.2 billion in market value. The setback shifts attention to the company's TRYNGOLZA launch.
Recursion Stock Surges Ahead of Goldman Sachs Conference Amid AI Drug Discovery Buzz
Recursion shares surged 12% to $3.87 on heavy volume ahead of a Goldman Sachs conference, as investors await updates on clinical trials, cash runway, and partnerships amid a broader AI drug-discovery rally.